Macular Edema - Pipeline Review, H1 2020
Macular Edema - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Pipeline Review, H1 2020, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape.
Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Macular Edema - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 1, 1, 1, 2, 11, 1 and 1 respectively.
Macular Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Pipeline Review, H1 2020, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape.
Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Macular Edema - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 1, 1, 1, 2, 11, 1 and 1 respectively.
Macular Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Macular Edema (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Macular Edema (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Macular Edema (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Macular Edema (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Macular Edema (Ophthalmology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Macular Edema (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Macular Edema (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Macular Edema - Overview
Macular Edema - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Macular Edema - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Macular Edema - Companies Involved in Therapeutics Development
Anew Oncology Inc
AsclepiX Therapeutics Inc
Celon Pharma SA
Clearside BioMedical Inc
Coherus BioSciences Inc
F. Hoffmann-La Roche Ltd
Formycon AG
Lupin Ltd
Luye Pharma Group Ltd
Mabion SA
OMEICOS Therapeutics GmbH
PharmAbcine Inc
Polus Inc
Profarma
Sustained Nano Systems LLC
Taiwan Liposome Co Ltd
Targeted Therapy Technologies LLC
Tarsius Pharma Ltd
Xbrane Biopharma AB
Macular Edema - Drug Profiles
ACX-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bevacizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Macular Edema - Dormant Projects
Macular Edema - Discontinued Products
Macular Edema - Product Development Milestones
Featured News & Press Releases
Apr 28, 2020: Clearside Biomedical revises NDA resubmission timeline and XIPERE commercial partnership with Bausch Health
Jan 28, 2020: Bausch Health and Clearside Biomedical announce publication of PIVOTAL phase 3 data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology
Aug 22, 2019: Clearside Biomedical provides new drug application update for XIPERE (triamcinolone acetonide suprachoroidal injectable suspension)
Jul 31, 2019: Clearside Biomedical announces multiple oral presentations delivered at the American Society of Retinal Specialists (ASRS) Annual Meeting
May 01, 2019: Clearside Biomedical presents on Triamcinolone at the American Uveitis Society Spring Meeting 2019
Apr 18, 2019: Clearside Biomedical announces presentations on its Suprachoroidal Space injection platform with Triamcinolone Acetonide at upcoming medical meetings
Feb 20, 2019: Clearside Biomedical receives notification of FDA acceptance of NDA filing for XIPERE (triamcinolone acetonide ophthalmic suspension) for suprachoroidal injection with PDUFA Date Set for October 19, 2019
Jan 20, 2019: Presentation of Clearside Biomedical’s Extension Study of PEACHTREE for XIPERE Exhibits Durability Following Second Dose
Dec 19, 2018: Clearside Biomedical submits New Drug Application for XIPERE for the treatment of Macular Edema associated with Uveitis
Oct 29, 2018: Presentation of additional analyses of Clearsides PEACHTREE clinical trial data further supports potential of XIPERE in treating uveitic macular edema
Oct 22, 2018: CLEARSIDE, XIPERE and PEACHTREE to be front and center at AAO 2018
Sep 18, 2018: Positive PEACHTREE Data to be Highlighted at EURETINA 2018
Sep 13, 2018: Data from Clearside Biomedical’s pivotal phase 3 PEACHTREE clinical trial in macular edema associated with non-infectious uveitis to be presented at the Retina Society 51st Annual Scientific Meeting
Sep 12, 2018: Single suprachoroidal steroid injection boosts visual acuity in patients with macular edema
Jul 16, 2018: Clearside Biomedical to Present Data from its Pivotal Phase 3 (PEACHTREE) Trial in Macular Edema Associated with Uveitis at the 2018 American Society of Retina Specialists Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Macular Edema - Overview
Macular Edema - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Macular Edema - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Macular Edema - Companies Involved in Therapeutics Development
Anew Oncology Inc
AsclepiX Therapeutics Inc
Celon Pharma SA
Clearside BioMedical Inc
Coherus BioSciences Inc
F. Hoffmann-La Roche Ltd
Formycon AG
Lupin Ltd
Luye Pharma Group Ltd
Mabion SA
OMEICOS Therapeutics GmbH
PharmAbcine Inc
Polus Inc
Profarma
Sustained Nano Systems LLC
Taiwan Liposome Co Ltd
Targeted Therapy Technologies LLC
Tarsius Pharma Ltd
Xbrane Biopharma AB
Macular Edema - Drug Profiles
ACX-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bevacizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Macular Edema - Dormant Projects
Macular Edema - Discontinued Products
Macular Edema - Product Development Milestones
Featured News & Press Releases
Apr 28, 2020: Clearside Biomedical revises NDA resubmission timeline and XIPERE commercial partnership with Bausch Health
Jan 28, 2020: Bausch Health and Clearside Biomedical announce publication of PIVOTAL phase 3 data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology
Aug 22, 2019: Clearside Biomedical provides new drug application update for XIPERE (triamcinolone acetonide suprachoroidal injectable suspension)
Jul 31, 2019: Clearside Biomedical announces multiple oral presentations delivered at the American Society of Retinal Specialists (ASRS) Annual Meeting
May 01, 2019: Clearside Biomedical presents on Triamcinolone at the American Uveitis Society Spring Meeting 2019
Apr 18, 2019: Clearside Biomedical announces presentations on its Suprachoroidal Space injection platform with Triamcinolone Acetonide at upcoming medical meetings
Feb 20, 2019: Clearside Biomedical receives notification of FDA acceptance of NDA filing for XIPERE (triamcinolone acetonide ophthalmic suspension) for suprachoroidal injection with PDUFA Date Set for October 19, 2019
Jan 20, 2019: Presentation of Clearside Biomedical’s Extension Study of PEACHTREE for XIPERE Exhibits Durability Following Second Dose
Dec 19, 2018: Clearside Biomedical submits New Drug Application for XIPERE for the treatment of Macular Edema associated with Uveitis
Oct 29, 2018: Presentation of additional analyses of Clearsides PEACHTREE clinical trial data further supports potential of XIPERE in treating uveitic macular edema
Oct 22, 2018: CLEARSIDE, XIPERE and PEACHTREE to be front and center at AAO 2018
Sep 18, 2018: Positive PEACHTREE Data to be Highlighted at EURETINA 2018
Sep 13, 2018: Data from Clearside Biomedical’s pivotal phase 3 PEACHTREE clinical trial in macular edema associated with non-infectious uveitis to be presented at the Retina Society 51st Annual Scientific Meeting
Sep 12, 2018: Single suprachoroidal steroid injection boosts visual acuity in patients with macular edema
Jul 16, 2018: Clearside Biomedical to Present Data from its Pivotal Phase 3 (PEACHTREE) Trial in Macular Edema Associated with Uveitis at the 2018 American Society of Retina Specialists Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Macular Edema, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Macular Edema - Pipeline by Anew Oncology Inc, H1 2020
Macular Edema - Pipeline by AsclepiX Therapeutics Inc, H1 2020
Macular Edema - Pipeline by Celon Pharma SA, H1 2020
Macular Edema - Pipeline by Clearside BioMedical Inc, H1 2020
Macular Edema - Pipeline by Coherus BioSciences Inc, H1 2020
Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Macular Edema - Pipeline by Formycon AG, H1 2020
Macular Edema - Pipeline by Lupin Ltd, H1 2020
Macular Edema - Pipeline by Luye Pharma Group Ltd, H1 2020
Macular Edema - Pipeline by Mabion SA, H1 2020
Macular Edema - Pipeline by OMEICOS Therapeutics GmbH, H1 2020
Macular Edema - Pipeline by PharmAbcine Inc, H1 2020
Macular Edema - Pipeline by Polus Inc, H1 2020
Macular Edema - Pipeline by Profarma, H1 2020
Macular Edema - Pipeline by Sustained Nano Systems LLC, H1 2020
Macular Edema - Pipeline by Taiwan Liposome Co Ltd, H1 2020
Macular Edema - Pipeline by Targeted Therapy Technologies LLC, H1 2020
Macular Edema - Pipeline by Tarsius Pharma Ltd, H1 2020
Macular Edema - Pipeline by Xbrane Biopharma AB, H1 2020
Macular Edema - Dormant Projects, H1 2020
Macular Edema - Discontinued Products, H1 2020
Number of Products under Development for Macular Edema, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Macular Edema - Pipeline by Anew Oncology Inc, H1 2020
Macular Edema - Pipeline by AsclepiX Therapeutics Inc, H1 2020
Macular Edema - Pipeline by Celon Pharma SA, H1 2020
Macular Edema - Pipeline by Clearside BioMedical Inc, H1 2020
Macular Edema - Pipeline by Coherus BioSciences Inc, H1 2020
Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Macular Edema - Pipeline by Formycon AG, H1 2020
Macular Edema - Pipeline by Lupin Ltd, H1 2020
Macular Edema - Pipeline by Luye Pharma Group Ltd, H1 2020
Macular Edema - Pipeline by Mabion SA, H1 2020
Macular Edema - Pipeline by OMEICOS Therapeutics GmbH, H1 2020
Macular Edema - Pipeline by PharmAbcine Inc, H1 2020
Macular Edema - Pipeline by Polus Inc, H1 2020
Macular Edema - Pipeline by Profarma, H1 2020
Macular Edema - Pipeline by Sustained Nano Systems LLC, H1 2020
Macular Edema - Pipeline by Taiwan Liposome Co Ltd, H1 2020
Macular Edema - Pipeline by Targeted Therapy Technologies LLC, H1 2020
Macular Edema - Pipeline by Tarsius Pharma Ltd, H1 2020
Macular Edema - Pipeline by Xbrane Biopharma AB, H1 2020
Macular Edema - Dormant Projects, H1 2020
Macular Edema - Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development for Macular Edema, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
Anew Oncology Inc
AsclepiX Therapeutics Inc
Celon Pharma SA
Clearside BioMedical Inc
Coherus BioSciences Inc
F. Hoffmann-La Roche Ltd
Formycon AG
Lupin Ltd
Luye Pharma Group Ltd
Mabion SA
OMEICOS Therapeutics GmbH
PharmAbcine Inc
Polus Inc
Profarma
Sustained Nano Systems LLC
Taiwan Liposome Co Ltd
Targeted Therapy Technologies LLC
Tarsius Pharma Ltd
Xbrane Biopharma AB
Number of Products under Development for Macular Edema, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
Anew Oncology Inc
AsclepiX Therapeutics Inc
Celon Pharma SA
Clearside BioMedical Inc
Coherus BioSciences Inc
F. Hoffmann-La Roche Ltd
Formycon AG
Lupin Ltd
Luye Pharma Group Ltd
Mabion SA
OMEICOS Therapeutics GmbH
PharmAbcine Inc
Polus Inc
Profarma
Sustained Nano Systems LLC
Taiwan Liposome Co Ltd
Targeted Therapy Technologies LLC
Tarsius Pharma Ltd
Xbrane Biopharma AB
